개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 87 - 93 (7page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazineincreases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The relative acceptabilitiesof these formulations may influence patient adherence; however, they have not been compared to date. This studyaimed to evaluate the acceptabilities of the 2 formulations of CR mesalazine in relation to patient adherence using a crossoverquestionnaire survey. Methods: UC patients were randomly assigned to 2 groups in a 1:1 ratio. Patients in each group tookeither 4 g of CR mesalazine tablets or granules for 6 to 9 weeks, and then switched to 4 g of the other formulation for a further 6to 9 weeks. The acceptability and efficacy were evaluated by questionnaires, and adherence was assessed using a visual analogscale. The difference in acceptabilities between the 2 formulations and its impact on adherence were assessed. Results: A totalof 49 patients were prospectively enrolled and 33 patients were included in the analysis. Significantly more patients found thetablets to be less acceptable than the granules (76% vs. 33%, P=0.0005). The granules were preferable to the tablets when the 2formulations were compared directly (73% vs. 21%, P=0.004), for their portability, size, and numbers of pills. The adherence ratewas slightly better among patients taking the granules (94% vs. 91%) during the observation period, but the difference was notsignificant (P=0.139). Conclusion: CR mesalazine granules are more acceptable than tablets, and may therefore be a better optionfor long-term medication. (Intest Res 2019;17:87-93)
목차
등록된 정보가 없습니다.
참고문헌 (14)
참고문헌 신청
Magro F / 2017 / Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders / J Crohns Colitis 11:649~670
Kane S / 2003 / Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis / Am J Med 114:39~43
Kawakami A / 2013 / Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission : a prospective cohort study / J Gastroenterol 48:1006~1015
Hanauer S / 1993 / Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group / Am J Gastroenterol 88:1188~1197
Flourié B / 2013 / Randomised clinical trial:once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis / Aliment Pharmacol Ther 37:767~775
Kane S / 2003 / Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis / Am J Med 114:39~43
Kawakami A / 2013 / Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission : a prospective cohort study / J Gastroenterol 48:1006~1015
Hanauer S / 1993 / Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group / Am J Gastroenterol 88:1188~1197
Flourié B / 2013 / Randomised clinical trial:once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis / Aliment Pharmacol Ther 37:767~775
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Corrigendum : Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
Intestinal research
2020 .01
-
Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
Intestinal research
2017 .01
-
Long lasting mesalazine-induced pancytopenia in a patient with ulcerative colitis
의생명과학
2019 .01
-
Factors related to Quality of Life of Patients with Ulcerative Colitis
성인간호학회 학술대회
2015 .04
-
Ulcerative Colitis and Patient’s Quality of Life, Especially in Early Stage
Gut and Liver
2022 .05
-
Comparison of efficacy of multimatrix mesalazine 4.8 g/ day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
Intestinal research
2017 .01
-
Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis?
Gut and Liver
2021 .09
-
청소년궤양성 대장염 환자의 사상체질요법에 대한 증례보고
대한한방내과학회지
2017 .01
-
Pyoderma Gangrenosum of the Chest Wall in a Male Patient with Ulcerative Colitis
대한내과학회지
2021 .02
-
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
2015 .01
-
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Intestinal research
2023 .01
-
The role and prospect of tofacitinib in patients with ulcerative colitis
Intestinal research
2023 .01
-
Comparison of the healing effects of mesazaline and Ganoderma lucidum in acetic acid-induced colitis in rats
Annals of Surgical Treatment and Research
2022 .01
-
Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
Gut and Liver
2021 .11
-
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
Intestinal research
2022 .04
-
Mitochondrial dysfunction of epithelial cell drives submucosal thickening through inflammatory fibroblasts in ulcerative colitis
한국실험동물학회 학술발표대회 논문집
2025 .02
-
Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China
Intestinal research
2023 .04
-
The Clinical Significance and Risk Factors of Colorectal Stricture in Ulcerative Colitis
Gut and Liver
2020 .01
-
Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
Gut and Liver
2021 .11
-
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Gut and Liver
2022 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0